Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will ...
Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The big-time BARDA contracts keep rolling in, this time for infectious disease biotech and Merck partner ModeX Therapeutics. The company has hauled in a $168 million contract from the Biomedical ...
GlobalData on MSN
ModeX starts dosing in MDX2003 trial for B-cell lymphoma
The trial includes dose-escalation and dose-expansion segments.
Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ModeX Therapeutics Inc., an OPKO Health company, announced the formation of a Scientific Advisory Board to support the development of its immunology and oncology pipeline, which includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results